Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.

Autor:	Locatelli F; Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: franco.locatelli@opbg.net., Antmen B; Division of Pediatric Hematology and Oncology and Stem Cell Transplantation, Department of Pediatrics, Acıbadem Adana Hospital, Adana, Türkiye., Kang HJ; Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, South Korea., Koh K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan., Takahashi Y; Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan., Kupesiz A; Paediatric Hematology Oncology, Akdeniz University School of Medicine, Antalya, Türkiye., Dias Matos MGA; GRAACC, São Paulo, Brazil., Chopra Y; Division of Hematology/Oncology, The Hospital for Sick Children, The University of Toronto, Toronto, ON, Canada., Bhat S; Mazumdar Shaw Medical Center, Narayana Health City, Bangalore, India., Im HJ; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, South Korea., Güngör T; Department of Hematology/Oncology/Immunology, Gene Therapy, and Stem Cell Transplantation, University Children's Hospital Zürich, Eleonore Foundation & Children's Research Center, Zurich, Switzerland., Lu MY; Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan., Stefanelli T; Novartis Pharma, Basel, Switzerland., Rosko C; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., St Pierre A; Novartis Pharma, Basel, Switzerland., Burock K; Novartis Pharma, Basel, Switzerland., Smith Y; Novartis Ireland Limited, Dublin, Ireland., Sinclair K; Novartis Pharma, Basel, Switzerland., Diaz-de-Heredia C; Division of Pediatric Hematology and Oncology and Stem Cell Transplantation, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	The Lancet. Haematology [Lancet Haematol] 2024 Aug; Vol. 11 (8), pp. e580-e592. Date of Electronic Publication: 2024 Jul 10.
DOI:	10.1016/S2352-3026(24)00174-1
Abstrakt:	Background: Chronic graft-versus-host disease (GVHD) is a debilitating, and sometimes life threatening, complication of allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the activity, pharmacokinetics, and safety of ruxolitinib added to corticosteroids in paediatric patients (ie, <18 years) with moderate-to-severe chronic GVHD. Methods: In this single-arm, phase 2 study, patients were recruited at 21 hospitals or clinics across 14 countries in Asia, Europe, and Canada. Eligible patients were aged 28 days to younger than 18 years, had undergone allogenic HSCT, and had been diagnosed with treatment-naive or corticosteroid-refractory moderate-to-severe chronic GVHD, per 2014 National Institutes of Health consensus criteria. Patients received oral ruxolitinib dosing on the basis of their age at the start of treatment: those aged 12 years to younger than 18 years received 10 mg twice daily (age ≥12 to <18 years group), those aged 6 years to younger than 12 years (age ≥6 to <12 years group) received 5 mg twice daily, and those aged 2 years to younger than 6 years received 4 mg/m 2 twice daily (age ≥2 to <6 years group). Treatment was to be administered in 28-day cycles for approximately 36 months, alongside supportive treatment per institutional guidelines. The primary activity endpoint was overall response rate at cycle 7 day 1. Activity and safety analyses are reported in the full analysis set, which included all patients who received at least one dose of ruxolitinib. Here we report the prespecified interim analysis, scheduled to occur after all patients had completed 1 year of treatment or discontinued treatment, and the results for the primary endpoint evaluation reported here is to be considered final. This study is registered with ClinicalTrials.gov, NCT03774082, enrolment is complete, and the study is ongoing. Findings: Between May 20, 2020, and Sept 17, 2021, 48 patients were screened, of whom 45 were enrolled and received at least one dose of study drug (median age was 11·0 years [IQR 7·2-14·3], 16 [36%] were female, 29 [64%] were male, 21 [47%] were White, one [2%] was Black or African American, 23 [51%] were Asian, 17 [38%] were treatment-naive, 28 [62%] were corticosteroid-refractory). As of data cutoff (Oct 19, 2022), after a median ruxolitinib exposure of 55·1 weeks (IQR 13·1-75·3), the overall response rate at cycle 7 day 1 was 40·0% (18 of 45; 90% CI 27·7-53·3), with responses seen in seven (41%) of 17 treatment-naive patients and 11 (39%) of 28 corticosteroid-refractory patients. The most common treatment-related adverse events of grade 3 or worse were neutropenia (eight [18%] of 45) and thrombocytopenia (six [13%]). Seven (16%) patients had grade 3 or worse serious treatment-related adverse events; the most common was hyponatraemia (two [4%] of 45). Three (7%) patients died while on-treatment (within 30 days of treatment discontinuation), one due to Aspergillus infection, one due to septic shock, and one due to acute respiratory distress syndrome; none were considered to be related to study drug. Interpretation: Pending final analysis, this study suggests that ruxolitinib is active and well tolerated in both treatment-naive and corticosteroid-refractory patients aged 2 years to younger than 18 years with chronic GVHD, thereby supporting its use in this patient population. The safety profile of ruxolitinib in this patient population is consistent with that of adults. Final analysis of this study will provide further information on the long-term benefits of ruxolitinib in children with chronic GVHD. Funding: Novartis. Competing Interests: Declaration of interests FL has participated in speaker bureaus for Amgen, Bluebird Bio, BMS, Medac Pharma, Miltenyi Biotec, Neovii, Novartis, and SOBI. HJK has received consulting fees from Structure Therapeutics (GPCR) and is on Data Safety Monitoring Boards or advisory boards with Jazz Pharmaceuticals, Novartis, Sanofi, Recordati, and Takeda. CD-d-H has received royalties from Jazz Pharmaceuticals and Vertex; received honoraria from Novartis; received meeting and travel support from Jazz Pharmaceuticals and Novartis; and has participated on a data safety monitoring board for Novartis. TS, CR, ASP, KB, YS, and KS are employees of Novartis. TS, KB, ASP, YS, and KS hold shares in Novartis. All other authors declare no competing interests. (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu